Question

Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019, Camdens fiscal year ends on December 31. Its financial statements are issued in April 2018 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $9,000,000 at the banks prime rate (12.5% at the time b. On October 1, borrowed $6 The company will pay no commitment fees. million cash from Second Commercial Bank under the line of credit and issued a five-month promissory note. Interest at the prime rate of 12% was payable at matur ity Management planned to issue 10-year bonds in February to repay the note. C. Received $3,000 of refundable deposits reusable container d. For the September-December period, sales on account total nDecember for reusable containers used to transport and store chemical-based products ed $4,400,000. The state sales tax rate is 3% and the local sales tax this ls a summary lournal entry for the many individual sales trnsactions for the period) e. Recorded the adjusting entry for accrued interest 2019 f In February, issued $3 million of 10 year bonds at face value and paid the bank loan on the March 1 due date g. Half of the storage containers covered by refundable deposits were returned in March. The remaining containers are expected to be returned during the next six months Required: 1. Prepare the appropriate journal entries for 2018 and 2019 transactions. 2. Prepare the current and long-term liability sections of the December 31, 2018, balance sheet. Trade accounts payable on that date were $273,000.
0 0
Add a comment Improve this question Transcribed image text
Answer #1

a) No entry Required. The reason is that the money has not yet been borrowed and its only negotiated

b)

Debit Credit
Cash $ 6,000,000.00
Notes Payable $ 6,000,000.00

c)

Debit Credit
Cash $          3,000.00
Liability for refundable deposits $          3,000.00

d)

Debit Credit
Accounts receivable (4,400,000 x (1+0.03+0.03)) $ 4,664,000.00
Sales revenue $ 4,400,000.00
Sales tax payable [(3% + 3%) x 4,400,000] $      264,000.00

e)

Debit Credit
Interest expense (12% x $6,000,000 x 3/12) $      180,000.00
Interest payable $      180,000.00

f)

Debit Credit
1 Cash $ 3,000,000.00
Bonds payable $ 3,000,000.00
2 Notes payable $ 6,000,000.00
Interest payable $      180,000.00
Interest expense (12% x 6,000,000 x 2/12) $      120,000.00
Cash $ 6,300,000.00

G)

Debit Credit
Liability for refundable deposits (1/2 x 3,000) $          1,500.00
Cash $          1,500.00

2)

Current Liabilities
Accounts payable $      273,000.00
Current portion of notes payable $ 3,000,000.00
Sales tax payable $      264,000.00
Interest payable $      180,000.00
Liability for refundable deposits $          3,000.00
Total current liabilities $ 3,720,000.00
Long-term Liabilities
Note payable to be refinances on long-term basis $ 3,000,000.00
Add a comment
Know the answer?
Add Answer to:
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Your Answer:

Post as a guest

Your Name:

What's your source?

Earn Coins

Coins can be redeemed for fabulous gifts.

Not the answer you're looking for? Ask your own homework help question. Our experts will answer your question WITHIN MINUTES for Free.
Similar Homework Help Questions
  • 2 Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of...

    2 Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden's fiscal year ends on December 31. Its financial statements are issued in April. 2018 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $33,000,000 at the bank's prime rate (15.5% at the time). The company will pay no commitment fees. b. On October...

  • Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $14,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $11...

  • Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $17,000,000 at the bank’s prime rate (12.5% at the time). The company will pay no commitment fees. On October 1, borrowed $14...

  • Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $14,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $11...

  • Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden's fiscal year ends on December 31. Its financial statements are issued in April. 2021 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $10,000,000 at the bank's prime rate (12.5% at the time). The company will pay no commitment fees. b. On October 1,...

  • Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden's fiscal year ends on December 31. Its financial statements are issued in April. 2021 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $33,000,000 at the bank's prime rate (15.5% at the time). The company will pay no commitment fees. b. On October 1,...

  • Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden's fiscal year ends on December 31. Its financial statements are issued in April. 2021 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $20,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees. b. On October 1,...

  • Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden's fiscal year ends on December 31. Its financial statements are issued in April. 2021 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $20,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees. b. On October 1,...

  • Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden's fiscal year ends on December 31. Its financial statements are issued in April. 2021 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $16,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees. b. On October 1,...

  • Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...

    Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden's fiscal year ends on December 31. Its financial statements are issued in April. 2021 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $23,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees. b. On October 1,...

ADVERTISEMENT
Free Homework Help App
Download From Google Play
Scan Your Homework
to Get Instant Free Answers
Need Online Homework Help?
Ask a Question
Get Answers For Free
Most questions answered within 3 hours.
ADVERTISEMENT
ADVERTISEMENT
Active Questions
ADVERTISEMENT